Advisory Research Inc Vaxcyte, Inc. Transaction History

Advisory Research Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$45.35 - $63.41 $1.08 Million - $1.51 Million	-23,794 Reduced 57.68%	17,461 $1.1 Million
Q3 2023 Nov 13, 2023	BUY	$46.0 - $53.1 $300,702 - $347,114	6,537 Added 18.83%	41,255 $2.1 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $1.2 Million - $1.88 Million	34,718 New	34,718 $1.73 Million
Q4 2022 Feb 13, 2023	BUY	$20.58 - $47.95 $88,576 - $206,376	4,304 New	4,304 $206,000

358

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.34B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.